Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Additional Omapro Trials Needed, FDA Tells ChemGenex In Complete Response Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA reservations mirror those outlined about need for validated assay test at March 22 ODAC meeting.

You may also be interested in...



Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine

Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.

Teva’s Synribo Clears FDA For Third-Line Chronic Myeloid Leukemia

Omacetaxine, which was originally submitted by ChemGenex as Omapro, demonstrated response rates of 14% to 18% in patients who had failed two or more tyrosine kinase inhibitors. It enters a crowded space that is likely to add a new member, Ariad’s ponatinib, in the coming months.

A Tale Of Two Targeted Therapies

FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel